Carboplatin + Paclitaxel
Treatment for Ovarian Cancer
Typical Dosage: Carboplatin AUC 5-6 + Paclitaxel 175 mg/m2 IV q3w for 6 cycles
Effectiveness
75%
Safety Score
30%
Clinical Trials
347
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
Carboplatin AUC 5-6 + Paclitaxel 175 mg/m2 IV q3w for 6 cycles
Time to Effect
1-2 months
Treatment Duration
4.5-6 months
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,000
Monitoring:$7,500
Side Effect Mgmt:$7,500
Total Annual:$20,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
2
Outcome-Based Costs
Cost per Responder
$26,667
Cost per Remission
$50,000
Carboplatin + Paclitaxel Outcomes
for Ovarian Cancer
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+75%
Remission Rate
+40%
Common Side Effects
Myelosuppression (Neutropenia, Anemia)
+70%
Alopecia
+85%
Peripheral Neuropathy
+40%
Nausea/Vomiting
+60%
Fatigue
+75%
Sources:
Active Clinical Trials
2 active trials recruiting for Carboplatin + Paclitaxel in Ovarian Cancer
Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer
NCT03025477RECRUITINGPHASE2
84 participants
INTERVENTIONAL
Dijon, France +6 more
Started: Oct 1, 2016
Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
NCT06437353RECRUITINGPHASE2
74 participants
INTERVENTIONAL
Hefei, China
Started: May 25, 2024
Completed Clinical Trials
10 completed trials for Carboplatin + Paclitaxel in Ovarian Cancer
Salvage Ovarian FANG™ Vaccine + Carboplatinum
NCT01867086COMPLETEDPHASE2
1 participants
INTERVENTIONAL
Dallas, United States
Started: Jun 1, 2013
Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV
NCT00231075COMPLETEDPHASE2
75 participants
INTERVENTIONAL
Eaubonne, France +1 more
Started: Jan 1, 2001
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
NCT02107937COMPLETEDPHASE2
136 participants
INTERVENTIONAL
Brno, Czechia +12 more
Started: Nov 1, 2013
Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
NCT00193297COMPLETEDPHASE2
50 participants
INTERVENTIONAL
Started: Feb 1, 2002
Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer
NCT05963334COMPLETEDPHASE1, PHASE2
49 participants
INTERVENTIONAL
Cairo, Egypt
Started: Jan 1, 2015
Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer
NCT02312661COMPLETEDPHASE1
15 participants
INTERVENTIONAL
Groningen, Netherlands
Started: Oct 5, 2015
Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin
NCT00181701COMPLETEDPHASE2
46 participants
INTERVENTIONAL
Started: Oct 1, 2004
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
NCT01616303COMPLETEDPHASE2
97 participants
INTERVENTIONAL
Farmington, United States +1 more
Started: Jun 15, 2012
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
NCT01015118COMPLETEDPHASE3
1.37K participants
INTERVENTIONAL
Tucson, United States +280 more
Started: Nov 17, 2009
Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)
NCT00129727COMPLETEDPHASE2
62 participants
INTERVENTIONAL
Started: Jun 1, 2005
Showing 20 of 349 total trials